Morgan Stanley Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX - Free Report) had its target price decreased by Morgan Stanley from $7.00 to $6.00 in a report issued on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

GDRX has been the subject of a number of other research reports. Citigroup dropped their target price on GoodRx from $10.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Barclays decreased their price objective on GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, November 11th. Finally, Mizuho assumed coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $8.37.

GoodRx Price Performance

NASDAQ:GDRX traded down $0.13 on Tuesday, reaching $4.46. 1,557,477 shares of the company's stock traded hands, compared to its average volume of 1,421,799. The stock has a 50-day simple moving average of $5.53 and a 200-day simple moving average of $7.06. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx has a 12 month low of $4.09 and a 12 month high of $9.26. The firm has a market cap of $1.70 billion, a PE ratio of -148.00, a P/E/G ratio of 3.54 and a beta of 1.29.

Institutional Trading of GoodRx

Several large investors have recently added to or reduced their stakes in GDRX. Liontrust Investment Partners LLP bought a new position in shares of GoodRx in the 2nd quarter valued at approximately $520,000. Legato Capital Management LLC bought a new position in GoodRx in the 2nd quarter valued at $805,000. Picton Mahoney Asset Management lifted its position in GoodRx by 24.3% during the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company's stock valued at $4,736,000 after purchasing an additional 118,703 shares during the period. ClariVest Asset Management LLC grew its stake in shares of GoodRx by 27.4% during the second quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company's stock worth $1,527,000 after purchasing an additional 42,097 shares during the period. Finally, American Century Companies Inc. bought a new stake in GoodRx in the second quarter valued at approximately $18,183,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.